EPO Does Not Improve Outcomes in Neonatal Hypoxic-Ischemic Encephalopathy
Death, neurodevelopmental impairment rates similar for newborns receiving erythropoietin, or placebo, combined with therapeutic hypothermia
Death, neurodevelopmental impairment rates similar for newborns receiving erythropoietin, or placebo, combined with therapeutic hypothermia
The primary endpoint was the number of patients who required no platelet transfusion priory to primary invasive procedure and no rescue therapy for bleeding for 7 days post-procedure.
Gender differences have been established for most chronic liver diseases but less is known with acute liver failure.
Timely administration of antibiotics is associated with a reduction in mortality among patients with cirrhosis and upper gastrointestinal bleeding (UGIB), according to a study published in the November issue of Clinical Gastroenterology and Hepatology.
The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.
Adding rifaximin to lactulose treatment for acute hepatic encephalopathy did not shorten hospital length of stay but it did lower readmission rates at 180 days, study authors reported in a study published in the Journal of Pharmacy Practice.
Complementary and alternative medicine (CAM)-induced drug-induced liver injury (DILI) is as severe in presentation as that seen with prescription medicine (PM)-induced DILI with higher rates of transplantation and lower transplant-free survival in patients who progress to acute liver failure, a new report in The American Journal of Gastroenterology has shown.
Mycophenolate mofetil appears safe and effective for the treatment of autoimmune hepatitis (AIH), according to the results of a study published in Alimentary Pharmacology & Therapeutics.
A case of hepatitis E virus (HEV) infection has been reported in a kidney transplant recipient, according to a research letter published online March 1 in the Annals of Internal Medicine.
Sorafenib was associated with a modest survival benefit in patients with advanced hepatocellular carcinoma (HCC), particiularly in patients with decompensation, data presented at The Liver Meeting® 2015 presented.